Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
40 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted pipeline therapeutics. The report provides comprehensive information on the Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - The report reviews Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted therapeutics and enlists all their major and minor projects - The report assesses Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) Overview 6 Therapeutics Development 7 Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Products under Development by Stage of Development 7 Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Products under Development by Therapy Area 8 Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Products under Development by Indication 9 Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Products under Development by Companies 13 Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Companies Involved in Therapeutics Development 21 Altor BioScience Corp 21 Cytune Pharma SAS 22 Nektar Therapeutics 23 Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Drug Profiles 24 ALT-803 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 CYP-0150 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Monoclonal Antibody Conjugates for Infectious Disease and Oncology - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 NKTR-255 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Recombinant Protein for Metabolic Disorders - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Dormant Projects 31 Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Featured News & Press Releases 32 Oct 28, 2016: Nektar Therapeutics to present data on NKTR-255 at the 2016 Society for Immunotherapy of Cancer Annual Meeting 32 Apr 27, 2016: Beike Biotechnology Unveils Comprehensive Cancer-treating Immunotherapy Program 32 Oct 06, 2015: Altor Bioscience Announces NCI Phase II SBIR Grant Award and Publication Supporting Ongoing Clinical Trial of IL-15 Super Agonist ALT-803 in Combination with Anti-CD20 Antibody Therapy for Relapsed / Refractory Non-Hodgkin Lymphoma 32 Nov 04, 2014: Altor BioScience Initiates Clinical Development of its Novel IL-15 Super Agonist ALT-803 for Relapsed / Refractory Multiple Myeloma Supported by a Newly Awarded Phase II SBIR Grant from NCI 33 Aug 19, 2014: Altor BioScience Awarded SBIR Phase II Grant by NCI for Clinical Development of its Novel IL-15 Super Agonist for Non-muscle Invasive Bladder Cancer 34 Aug 15, 2013: Altor BioScience Launches its Proprietary IL-15 Superagonist ALT-803 into Clinical Trials against Cancer 35 Sep 27, 2012: Altor BioScience Awarded Two SBIR Phase I Grants by NCI for Research on its Novel IL-15 Super Agonists for Hematologic Cancers 36 Apr 30, 2012: Altor And Melanoma Research Alliance To Co-Support Clinical Studies Of ALT-803 To Treat Metastatic Melanoma 37 Aug 17, 2011: Altor Receives $225,279 SBIR Phase I Grant For Research On ALT-803 To Treat Bladder Cancer 37 Jun 28, 2011: Florida Biologix Signs Manufacturing Agreement With Altor BioScience 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 39 Disclaimer 40
List of Tables Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Assessment by Monotherapy/Combination Products, H2 2016 15 Number of Products by Stage and Mechanism of Action, H2 2016 16 Number of Products by Stage and Route of Administration, H2 2016 18 Number of Products by Stage and Molecule Type, H2 2016 20 Pipeline by Altor BioScience Corp, H2 2016 21 Pipeline by Cytune Pharma SAS, H2 2016 22 Pipeline by Nektar Therapeutics, H2 2016 23 Dormant Projects, H2 2016 31 List of Figures Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Top 10 Indication, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 12 Assessment by Monotherapy/Combination Products, H2 2016 15 Number of Products by Stage and Mechanism of Actions, H2 2016 16 Number of Products by Routes of Administration, H2 2016 17 Number of Products by Stage and Routes of Administration, H2 2016 17 Number of Products by Molecule Types, H2 2016 19 Number of Products by Stage and Molecule Type, H2 2016 19
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
